Trial Profile

B7-H3-Targeted Chimeric Antigen Receptor (CAR) T Cells in Treating Patients With Recurrent or Refractory Glioblastoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti B7 H3 chimeric antigen receptor T-cell therapy BoYuan RunSheng Pharma (Primary) ; Anti B7 H3 chimeric antigen receptor T-cell therapy BoYuan RunSheng Pharma (Primary) ; Temozolomide
Indications Glioblastoma
Focus Therapeutic Use

Most Recent Events

25 Dec 2022 Planned End Date changed from 1 Jul 2024 to 1 Aug 2025.
25 Dec 2022 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2025.
17 May 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com